JP2019512472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512472A5 JP2019512472A5 JP2018545828A JP2018545828A JP2019512472A5 JP 2019512472 A5 JP2019512472 A5 JP 2019512472A5 JP 2018545828 A JP2018545828 A JP 2018545828A JP 2018545828 A JP2018545828 A JP 2018545828A JP 2019512472 A5 JP2019512472 A5 JP 2019512472A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 18
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 claims 18
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 14
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 210000002966 serum Anatomy 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 108010028554 LDL Cholesterol Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 2
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 101710172072 Kexin Proteins 0.000 claims 1
- 108010044159 Proprotein Convertases Proteins 0.000 claims 1
- 102000006437 Proprotein Convertases Human genes 0.000 claims 1
- 108090000787 Subtilisin Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002027 evolocumab Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022040874A JP2022078306A (ja) | 2016-03-03 | 2022-03-16 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| JP2024025078A JP2024059787A (ja) | 2016-03-03 | 2024-02-22 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302907P | 2016-03-03 | 2016-03-03 | |
| US62/302,907 | 2016-03-03 | ||
| PCT/US2017/020221 WO2017151783A1 (en) | 2016-03-03 | 2017-03-01 | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022040874A Division JP2022078306A (ja) | 2016-03-03 | 2022-03-16 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512472A JP2019512472A (ja) | 2019-05-16 |
| JP2019512472A5 true JP2019512472A5 (enExample) | 2020-03-05 |
| JP7541810B2 JP7541810B2 (ja) | 2024-08-29 |
Family
ID=58361088
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545828A Active JP7541810B2 (ja) | 2016-03-03 | 2017-03-01 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| JP2022040874A Pending JP2022078306A (ja) | 2016-03-03 | 2022-03-16 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| JP2024025078A Pending JP2024059787A (ja) | 2016-03-03 | 2024-02-22 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022040874A Pending JP2022078306A (ja) | 2016-03-03 | 2022-03-16 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| JP2024025078A Pending JP2024059787A (ja) | 2016-03-03 | 2024-02-22 | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170253666A1 (enExample) |
| EP (1) | EP3423157A1 (enExample) |
| JP (3) | JP7541810B2 (enExample) |
| KR (1) | KR102456731B1 (enExample) |
| CN (1) | CN109069868B (enExample) |
| AU (1) | AU2017227713B2 (enExample) |
| CA (1) | CA3016764A1 (enExample) |
| EA (1) | EA201891979A1 (enExample) |
| IL (1) | IL261420A (enExample) |
| MA (1) | MA43734A (enExample) |
| MX (1) | MX2018010401A (enExample) |
| WO (1) | WO2017151783A1 (enExample) |
| ZA (1) | ZA201805403B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| CN109069641A (zh) * | 2016-04-28 | 2018-12-21 | 瑞泽恩制药公司 | 用于治疗家族性高胆固醇血症患者的方法 |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
| WO2021001804A1 (en) * | 2019-07-04 | 2021-01-07 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| JP2023538522A (ja) * | 2020-08-07 | 2023-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
| US20240141029A1 (en) * | 2021-03-05 | 2024-05-02 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| WO2025185644A1 (zh) * | 2024-03-05 | 2025-09-12 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体治疗高血脂症的用途及方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| AU781295B2 (en) | 1999-02-12 | 2005-05-12 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| WO2002067901A1 (en) | 2001-02-22 | 2002-09-06 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
| CN1615440A (zh) | 2001-11-16 | 2005-05-11 | 杰南技术公司 | 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法 |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| US20110097330A1 (en) | 2005-03-11 | 2011-04-28 | Genentech, Inc. | Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
| KR101503937B1 (ko) | 2006-12-08 | 2015-03-18 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Ａｎｇｐｔｌ３ 에 대한 단일클론 항체 |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| JP5711671B2 (ja) | 2009-02-23 | 2015-05-07 | ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． | ポリコサノールナノ粒子 |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| BR112012000914B8 (pt) | 2009-07-14 | 2021-05-25 | Irm Llc | uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular |
| EP2521556B1 (en) | 2010-01-08 | 2018-05-30 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| KR20230107908A (ko) | 2011-06-21 | 2023-07-18 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그사용 방법 |
| EP2735315B1 (en) | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Stable protein-containing preparation containing argininamide or valinamide |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| AU2013334740A1 (en) | 2012-10-25 | 2015-04-02 | Medimmune, Llc | Stable, low viscosity antibody formulation |
| BR112015022624A2 (pt) | 2013-03-14 | 2017-10-31 | Uab Research Foundation | regime de dose, e, método para tratamento de aterosclerose |
| US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014274844B2 (en) | 2013-06-07 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| EP3071198A1 (en) | 2013-11-20 | 2016-09-28 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| KR102298476B1 (ko) | 2013-12-24 | 2021-09-03 | 아이오니스 파마수티컬즈, 인코포레이티드 | 안지오포이에틴-유사 3 발현의 조절 |
| CN106255755B (zh) | 2014-05-01 | 2020-07-24 | Ionis制药公司 | 用于调节血管生成素样蛋白3表达的组合物和方法 |
| RU2735521C2 (ru) * | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| AU2015289617B2 (en) | 2014-07-16 | 2021-04-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| JP6680758B2 (ja) | 2014-10-03 | 2020-04-15 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| HUE062709T2 (hu) | 2016-02-17 | 2023-11-28 | Regeneron Pharma | Módszerek az atherosclerosis kezelésére vagy megelõzésére ANGPTL3 inhibitor alkalmazásával |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| MX386832B (es) | 2016-04-08 | 2025-03-19 | Regeneron Pharma | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
| CN109069641A (zh) | 2016-04-28 | 2018-12-21 | 瑞泽恩制药公司 | 用于治疗家族性高胆固醇血症患者的方法 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US20200369760A1 (en) | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| JP2023538522A (ja) | 2020-08-07 | 2023-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
-
2017
- 2017-03-01 MA MA043734A patent/MA43734A/fr unknown
- 2017-03-01 EA EA201891979A patent/EA201891979A1/ru unknown
- 2017-03-01 US US15/446,720 patent/US20170253666A1/en not_active Abandoned
- 2017-03-01 WO PCT/US2017/020221 patent/WO2017151783A1/en not_active Ceased
- 2017-03-01 AU AU2017227713A patent/AU2017227713B2/en active Active
- 2017-03-01 CN CN201780014857.0A patent/CN109069868B/zh active Active
- 2017-03-01 CA CA3016764A patent/CA3016764A1/en active Pending
- 2017-03-01 MX MX2018010401A patent/MX2018010401A/es unknown
- 2017-03-01 JP JP2018545828A patent/JP7541810B2/ja active Active
- 2017-03-01 KR KR1020187028068A patent/KR102456731B1/ko active Active
- 2017-03-01 EP EP17712283.5A patent/EP3423157A1/en active Pending
-
2018
- 2018-08-14 ZA ZA2018/05403A patent/ZA201805403B/en unknown
- 2018-08-28 IL IL261420A patent/IL261420A/en unknown
-
2020
- 2020-03-03 US US16/808,058 patent/US12281173B2/en active Active
-
2022
- 2022-03-16 JP JP2022040874A patent/JP2022078306A/ja active Pending
-
2024
- 2024-02-22 JP JP2024025078A patent/JP2024059787A/ja active Pending